JP2023179457A5 - - Google Patents

Download PDF

Info

Publication number
JP2023179457A5
JP2023179457A5 JP2023145164A JP2023145164A JP2023179457A5 JP 2023179457 A5 JP2023179457 A5 JP 2023179457A5 JP 2023145164 A JP2023145164 A JP 2023145164A JP 2023145164 A JP2023145164 A JP 2023145164A JP 2023179457 A5 JP2023179457 A5 JP 2023179457A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
amino acid
acid sequence
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023145164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023179457A (ja
JP7719134B2 (ja
Filing date
Publication date
Priority claimed from JP2020554517A external-priority patent/JP7614842B2/ja
Application filed filed Critical
Publication of JP2023179457A publication Critical patent/JP2023179457A/ja
Publication of JP2023179457A5 publication Critical patent/JP2023179457A5/ja
Priority to JP2025123756A priority Critical patent/JP2025166834A/ja
Application granted granted Critical
Publication of JP7719134B2 publication Critical patent/JP7719134B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023145164A 2018-04-03 2023-09-07 抗原性エプスタインバーウイルスポリペプチド Active JP7719134B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025123756A JP2025166834A (ja) 2018-04-03 2025-07-24 抗原性エプスタインバーウイルスポリペプチド

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862652201P 2018-04-03 2018-04-03
US62/652,201 2018-04-03
JP2020554517A JP7614842B2 (ja) 2018-04-03 2019-04-02 抗原性エプスタインバーウイルスポリペプチド
PCT/US2019/025419 WO2019195314A2 (en) 2018-04-03 2019-04-02 Antigenic epstein barr virus polypeptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020554517A Division JP7614842B2 (ja) 2018-04-03 2019-04-02 抗原性エプスタインバーウイルスポリペプチド

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025123756A Division JP2025166834A (ja) 2018-04-03 2025-07-24 抗原性エプスタインバーウイルスポリペプチド

Publications (3)

Publication Number Publication Date
JP2023179457A JP2023179457A (ja) 2023-12-19
JP2023179457A5 true JP2023179457A5 (https=) 2024-05-23
JP7719134B2 JP7719134B2 (ja) 2025-08-05

Family

ID=66821298

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020554517A Active JP7614842B2 (ja) 2018-04-03 2019-04-02 抗原性エプスタインバーウイルスポリペプチド
JP2023145164A Active JP7719134B2 (ja) 2018-04-03 2023-09-07 抗原性エプスタインバーウイルスポリペプチド
JP2025123756A Pending JP2025166834A (ja) 2018-04-03 2025-07-24 抗原性エプスタインバーウイルスポリペプチド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020554517A Active JP7614842B2 (ja) 2018-04-03 2019-04-02 抗原性エプスタインバーウイルスポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025123756A Pending JP2025166834A (ja) 2018-04-03 2025-07-24 抗原性エプスタインバーウイルスポリペプチド

Country Status (5)

Country Link
US (4) US11617780B2 (https=)
EP (1) EP3773708A2 (https=)
JP (3) JP7614842B2 (https=)
CN (1) CN112512566A (https=)
WO (1) WO2019195314A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195314A2 (en) 2018-04-03 2019-10-10 Sanofi Antigenic epstein barr virus polypeptides
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
MA53158A (fr) * 2018-07-20 2021-05-26 Aicuris Gmbh & Co Kg Procédés de criblage et d'identification d'agents inhibant ou modulant le complexe de sortie nucléaire du virus de l'herpès
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
CN111154803B (zh) * 2020-01-10 2022-07-22 新乡医学院 一种重组EBV gHgL免疫原的制备方法及其应用
WO2021207595A1 (en) * 2020-04-10 2021-10-14 Vanderbilt University Recombinant vaccines and methods of use thereof
US20210322483A1 (en) 2020-04-16 2021-10-21 Ichilov Tech Ltd. Cell-derived particles presenting heterologous cd24 and use thereof in therapy
CN113144187B (zh) * 2021-01-28 2024-03-22 安徽智飞龙科马生物制药有限公司 一种含EB病毒gHgLgp42蛋白的自组装纳米颗粒及其制备方法与应用
EP4322997A4 (en) * 2021-04-13 2025-02-26 ModernaTX, Inc. EPSTEIN-BARR VIRUS mRNA VACCINES
WO2025186459A1 (en) * 2024-03-08 2025-09-12 Sanofi Antigenic epstein barr virus polypeptides
WO2025215618A1 (en) * 2024-04-12 2025-10-16 Seqirus Inc. Methods and reagents for treating or preventing ebv
CN120365380A (zh) * 2025-04-21 2025-07-25 易康生物(苏州)有限公司 一种嵌合设计的eb病毒抗原及其应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0312164A1 (en) * 1987-10-16 1989-04-19 Merck & Co. Inc. Purification of recombinant epstein-barr virus antigens from vero cells, yeast cells or L cells
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO2001075436A1 (en) 2000-04-03 2001-10-11 Board Of Trustees Of The Leland Stanford Junior University A method for protein structure alignment
ATE381575T1 (de) 2000-08-18 2008-01-15 Univ New York State Res Found Veränderte borrelia burgdorferi ospa
CN1659187A (zh) 2002-05-10 2005-08-24 新世纪药品有限公司 融合铁蛋白在疫苗和其他方面的应用
US7774185B2 (en) 2004-09-14 2010-08-10 International Business Machines Corporation Protein structure alignment using cellular automata
AU2006338570B2 (en) 2005-11-18 2013-07-11 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US7951770B2 (en) 2007-06-13 2011-05-31 Northwestern University Peptides, peptidomimetics and small molecule inhibitors of the Epstein-Barr virus mediated fusion and entry process
WO2009080719A1 (en) * 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccine
US20110117131A1 (en) 2008-04-09 2011-05-19 Ning Huang Production of OspA for Lyme Disease Control
AU2011252844B2 (en) 2010-05-14 2014-07-03 Baxalta GmbH Chimeric OspA genes, proteins, and methods of use thereof
WO2012006180A1 (en) 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
US20140227305A1 (en) 2010-08-25 2014-08-14 Romana Lange-Ruiss Epstein-barr-virus vaccine
WO2012139069A2 (en) 2011-04-07 2012-10-11 Neotope Biosciences Limited Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
EP2515112B1 (en) 2011-04-22 2015-08-12 Sysmex Corporation Method for electrochemically detecting analyte
JP5795184B2 (ja) * 2011-04-22 2015-10-14 国立大学法人 奈良先端科学技術大学院大学 被検物質の電気化学的検出方法
WO2013039792A1 (en) 2011-09-12 2013-03-21 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunogens based on an hiv-1 gp120 v1v2 epitope
EP2758038B1 (en) 2011-09-23 2018-05-30 The United States of America, as represented by The Secretary, Department of Health & Human Services Novel influenza hemagglutinin protein-based vaccines
WO2014018931A1 (en) 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
BR112015001390B1 (pt) * 2012-07-26 2024-04-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc Proteína de fusão, ácido nucleico isolado e uso de uma composição de vacina
EP2970398B1 (en) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
WO2015054639A1 (en) * 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus vaccines
JP6679484B2 (ja) 2013-12-11 2020-04-15 ザ ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド ヒトヘルペスウイルス三量体糖タンパク質B、三量体gBを含むタンパク質複合体、及びワクチンとしてのそれらの使用
CZ2014320A3 (cs) 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
US10363301B2 (en) 2014-05-27 2019-07-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Stabilized influenza hemagglutinin stem region trimers and uses thereof
US11191727B2 (en) 2014-12-31 2021-12-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multivalent nanoparticle-based vaccines
US9703095B2 (en) 2015-01-05 2017-07-11 Edward Pakhchyan Light modulator for MEMS display
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
WO2016138160A1 (en) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
EP3383426A1 (en) 2015-12-04 2018-10-10 Dana Farber Cancer Institute, Inc. Vaccination with mica/b alpha 3 domain for the treatment of cancer
WO2017172890A1 (en) 2016-03-29 2017-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion rsv f proteins and their use
JP6974358B2 (ja) 2016-06-07 2021-12-01 ドイチェス クレブスフォルシュンクスツェントルム Hpv l2ペプチドの免疫原性の改善
BR112018076015A8 (pt) 2016-06-17 2022-06-28 Sanofi Pasteur Formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado .
US10961283B2 (en) * 2016-06-27 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
US11572389B2 (en) 2017-01-27 2023-02-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
WO2018193063A2 (en) * 2017-04-19 2018-10-25 Institute For Research In Biomedicine Novel malaria vaccines and antibodies binding to plasmodium sporozoites
WO2019014569A1 (en) 2017-07-13 2019-01-17 City Of Hope EXPRESSION SYSTEM FOR EXPRESSING GLYCOPROTEIN COMPLEXES OF HERPESVIRUS
US11964006B2 (en) 2017-09-16 2024-04-23 City Of Hope Multivalent Epstein-Barr virus-like particles and uses thereof
MA50813A (fr) * 2017-11-21 2020-09-30 Modernatx Inc Vaccins contre le virus d'epstein-barr
WO2019161163A1 (en) 2018-02-16 2019-08-22 The Wistar Institute Of Anatomy And Biology Epstein-barr virus nucleic acid constructs and vaccines made therefrom, and methods of using same
WO2019195314A2 (en) 2018-04-03 2019-10-10 Sanofi Antigenic epstein barr virus polypeptides
KR20210018205A (ko) 2018-04-03 2021-02-17 사노피 항원성 OspA 폴리펩타이드
JP2021519600A (ja) 2018-04-03 2021-08-12 サノフイSanofi 抗原性インフルエンザ−フェリチンポリペプチド
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
EP4225360A1 (en) 2020-10-08 2023-08-16 Virothera Limited Vaccine compositions
EP4370686A4 (en) 2021-07-16 2025-10-15 California Inst Of Techn STOECHIOMETRIC EXPRESSION OF MESSENGER POLYCISTRONS

Similar Documents

Publication Publication Date Title
JP2023179457A5 (https=)
JP2025166834A5 (https=)
JP2012082206A5 (https=)
JP2006149365A5 (https=)
MX2019015502A (es) L-asparaginasa modificada.
JP2013520426A5 (https=)
JP2017048194A5 (https=)
JP2021520818A5 (https=)
JP2014000092A5 (https=)
JP2018504911A5 (https=)
JP2024041747A5 (https=)
JP2025507822A5 (https=)
JP2019500414A5 (https=)
JP2019214579A5 (https=)
FI3737399T3 (fi) ATF5-peptidivariantit ja niiden käytöt
MX2008009493A (es) Peptido novedoso y uso del mismo.
CN109937252A (zh) 重组dna聚合酶
MX2021004714A (es) Proteina cas9 modificada, y uso de la misma.
CN110799522A (zh) 用于治疗、改善或预防脑出血的肽及其用途
HK1215441A1 (zh) 人血清白蛋白结合化合物及其融合蛋白
WO2019094938A3 (en) Methods and compositions for the treatment of wounds
EA202190240A1 (ru) Варианты рекомбинантного белка
JP2024520868A5 (https=)
JP2020513810A5 (https=)
CU24609B1 (es) Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic